AQUESTIVE THERAPEUTICS

2,5100

17-апреля-25 16:45:00

15 мин. задержка

Акции

+0,0100

+0,40%

Сегодняшний диапазон

2,4700 - 2,5800

ISIN

N/A

Источник

NASDAQ

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

09 апр 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

01 апр 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

05 мар 2025 16:01:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

26 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

20 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

12 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

04 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

13 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

19 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

02 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

12 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04 ноя 2024 16:36:01 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

25 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

24 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

21 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

27 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

09 сен 2024 08:15:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

22 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

14 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 авг 2024 16:22:19 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.